---
document_datetime: 2023-09-21 17:55:53
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/novorapid-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: novorapid-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.5477345
conversion_datetime: 2025-12-14 14:44:23.830253
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## PROCEDURAL STEPS TAKEN AFTER AUTHORISATION

For procedures finalised after 1 September 2004 please refer to module 8B

| Scope                                                                                            | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|--------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Change of storage container of the active substance                                              | I/01                 | I/II                     | 18.11.99                            | _                                       |
| Additional pack size                                                                             | II/02                | II                       | 21.10.99                            | 08.02.00                                |
| Additional pack size 10 x 3 ml Novolet                                                           | II/03                | II                       | 21.10.99                            | 08.02.00                                |
| Additional pack size 5 x 10 ml NovoRapid                                                         | II/04                | II                       | 21.10.99                            | 08.02.00                                |
| Update of SPC and PL with regard to post prandial administration                                 | II/05                | II                       | 18.11.99                            | 13.04.00                                |
| Additional presentation: FlexPen                                                                 | II/06                | II                       | 28.08.00                            | 15.01.01                                |
| Update of SPC and PL with regard to 'early hypoglycaemia in general' and 'safe use in children'  | II/07                | II                       | 14.12.00                            | 23.04.01                                |
| Update of SPC and PL with regard to continuous subcutaneous insulin infusion for Novorapid vials | II/08                | II                       | 26.04.01                            | 13.07.01                                |
| Change in the test procedure of the active substance and medicinal product                       | I/09                 | I                        | 01.03.01                            | _                                       |
| Additional facility for purification of Insulin Aspart                                           | II/10                | II                       | 20.09.01                            | _                                       |
| Change in the batch size of the finished product                                                 | I/11                 | I/II                     | 13.12.01                            | _                                       |
| Change for the deletion of the bio identity test                                                 | II/12                | II                       | 21.02.02                            | _                                       |
| Update of the SPC and PL regarding the occurrence of fewer nocturnal hypoglycaemic episodes      | II/13                | II                       | 21.03.02                            | 15.07.02                                |
| Minor change of the manufacturing process of the active substance                                | I/14                 | I/II                     | 21.02.02                            | _                                       |
| Additional pack size 1x3ml FlexPen                                                               | I/15                 | I                        | 16.01.02                            | _                                       |
| New route of administration (intravenous)                                                        | X/16                 | X                        | 18.12.02                            | 04.06.03                                |
| Change in batch size for Novorapid vials                                                         | I/17                 | I/II                     | 30.05.02                            | _                                       |
| Change in batch size                                                                             | I/18                 | I/II                     | 27.06.02                            | _                                       |
| New route of administration (intravenous) for all presentations                                  | X/19                 | X                        | 18.12.02                            | 04.06.03                                |

1

1 October 2003 in accordance with Commission Regulation (EC) No 1085/2003: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended, and for variations after refers to a minor variation following the procedure set out in

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 61(3) of Council Directive 2001/83/EC.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.

1/2

<div style=\"page-break-after: always\"></div>

| Additional presentation: InnoLet                                                                       | II/21   | II   | 18.12.02   | 04.06.03   |
|--------------------------------------------------------------------------------------------------------|---------|------|------------|------------|
| Update of the SPC and PL with regard to continuous subcutaneous insulin infusion for all presentations | II/22   | II   | 23.01.03   | 06.06.03   |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process            | I/24    | I    | 20.06.03   | -          |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process            | I/25    | I    | 16.07.03   | -          |
| Minor changes in manufacture of the medicinal product                                                  | I/26    | I    | 25.09.03   | -          |
| Qualitative change to the active substance                                                             | X/27    | X    | 03.06.04   | 24.08.04   |
| Update of sections 4.4 and 4.8 of SPC and PL                                                           | II/28   | II   | 26.02.04   | 07.04.04   |
| General update of SPC and PL                                                                           | II/29   | II   | 26.02.04   | 07.04.04   |
| Update of or change to the pharmaceutical documentation                                                | II/30   | II   | 24.03.04   | -          |
| Update of or change to the pharmaceutical documentation                                                | II/31   | II   | 22.04.04   | -          |

2/2